NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS EPTIFIBATIDE (INTEGRILIN) PROTOCOL
|
|
- Lenard Hodge
- 6 years ago
- Views:
Transcription
1 NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE S EPTIFIBATIDE (INTEGRILIN) I. PURPOSE: A. Integrilin (Eptifibatide) is a specific and potent inhibitor of the platelet receptor glycoprotein IIb-IIIa, preventing binding of fibrinogen to GP IIb-IIIa, thus helping to prevent platelet aggregation. B. Integrilin (Eptifibatide) is indicated for the treatment of patients with acute coronary syndrome (unstable angina, non Q MI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). II. PATIENT SELECTION: The patient must meet some or all of the following criteria: A. Chest pain at rest (> 10 minutes duration) within the previous 24 hours. B. ECG abnormalities within 12 hours, defined as: ST segment depression > 0.5 mm, or T wave inversion > 1 mm, or ST segment elevation between 0.6 mm and 1 mm, or Positive CK-MB assay, or Positive Troponin T or I C. Percutaneous coronary intervention is planned within hours (angioplasty, atherectomy, stent placement). Date of Original: 4/99 Reviewed Revised 12/01 3/08 3/08 3/09 3/09 9/11 9/11 9/ /14 10/15 10/16 6/17 7
2 PAGE 2 III. CONTRAINDICATIONS: Because Integrilin (Eptifibatide) increases the risk of bleeding, it is contraindicated in the following situations: A. A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days. B. Severe hypertension (systolic blood pressure > 200mmHg or diastolic blood pressure > 110mmHg) not adequately controlled on antihypertensive therapy. C. Major surgery within preceding 6 weeks. D. History of stroke within 30 days, or any history of hemorrhagic stroke. E. Current or planned administration of another parenteral GP IIb-IIIa inhibitor. F. Platelet count < 100,000/mm3. G. Serum creatinine > 2 mg/dl (for the 180 mcg/kg bolus and the 2 mcg/kg/min infusion) or > 4mg/dL (for the 135 mcg/kg bolus and the 0.5 mcg/kg/min infusion). H. Dependency on renal dialysis. I. Known hypersensitivity to any component of the product. 7a EPTIFIBATICLE (INTEGRILLIN)
3 PAGE 3 IV. SPECIAL CONSIDERATIONS: A. At least two primary, preferably three, I.V. infusion lines, or per M.D. order, will be established prior to dosing with Integrilin (Eptifibatide) minimize venipunctures. B. Bleeding is the most common complication encountered during Integrilin (Eptifibatide) therapy. If bleeding cannot be controlled with pressure, infusion of etifibatide and concomitant heparin should be discontinued.. C. Arterial and venous punctures, IM injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes should be minimized. When obtaining I.V. access, noncompressible sites (e.g., subclavian or jugular veins) should be avoided. D. Before infusion of Integrilin eptifibatide, the following lab tests should be performed to identify pre-existing hemostatic abnormalities: hemoglobin and hematocrit, platelet count, serum creatinine, and PT/PTT. Lab testing to be order by physician. E. The PTT should be maintained between 50 and 70 seconds unless PCI is to be performed. During PCI, the ACT should be maintained between seconds. F. The PTT should be checked prior to arterial sheath removal. The sheath should not be removed unless the PTT is < 45 seconds. 7b
4 PAGE 4 G. In patients treated with heparin, bleeding can be minimized by close monitoring of the PTT. H. If the patient experiences a confirmed platelet decrease to < 100,000mm3, eptifibatide and heparin should be discontinued and the condition appropriately monitored and treated. I. In clinical studies, patients were enrolled up to 94 years of age, with no apparent difference in efficacy between the older and younger patients treated with eptifibatide. The incidence of bleeding complications was higher in the elderly patients, with the incremental risk of eptifibatideassociated bleeding greater in the older patients. J. Use toothettes for oral care. V. PROCEDURE: A. The patient and/or patient s family should be well informed by the physician of the risk of potential bleeding complications with the administration of Integrilin (Eptifibatide). B. After orders have been received from the cardiologist for the administration of Integrilin (Eptifibatide), all labs, per physician orders, should be drawn and lines placed prior to dosing the patient. C. Continue therapy with Heparin and aspirin as ordered by the physician during administration of Integrilin (Eptifibatide). Follow the IV Heparin protocol for PTT parameters/times to maintain target PTT between 50 and 70 seconds. 7c
5 PAGE 5 VI. DOSAGE AND ADMINISTRATION: A. The recommended adult dosage of eptifibatide in patients with acute coronary syndrome is an IV bolus of 180 mcg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2 mcg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. B. If a patient is to undergo PCI while receiving eptifibatide, consideration can be given to decreasing the infusion rate to 0.5 mcg/kg/min at the time of the procedure. C. In patients not presenting with acute coronary syndrome, and undergoing PCI, the recommended adult dosage of eptifibatide is an IV bolus of 135 mcg/kg, administered immediately before the initiation of PCI, followed by a continuous infusion of 0.5 mcg/kg/min for hours. D. Instructions for administration: 1. Integrilin (eptifibatide) solution should be inspected visually for particulate matter and discoloration prior to administration. 2. Integrilin may be administered in the same IV line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. It should not be administered through the same IV line as furosemide. 3. Integrilin (eptifibatide) may be administered in the same IV line with 0.9% NaCl or 0.9% NaCl 5% dextrose. The infusion may also contain up to 40mEq/L of potassium chloride. 4. The bolus dose of Integrilin (eptifibatide) should be withdrawn from the 10-ml vial into a syringe, and administered IV push over 1-2 minutes. Each 10-ml vial contains 20mg eptifibatide in sterile solution. 7d
6 PAGE 6 5. Immediately following the bolus dose administration, a continuous infusion of Integrilin (eptifibatide) should be initiated. When using an IV infusion pump, Integrilin (eptifibatide) should be administered undiluted directly from the 100-ml vial. This vial should be spiked with a vented infusion set, with care taken to center the spike within the circle on the stopper top. Each 100-ml vial contains 75 mg eptifibatide in sterile solution. 6. Integrilin (eptifibatide) is to be administered by volume according to patient weight. 7. Integrilin (eptifibatide) vials should be refrigerated at degrees F. 8. The physician will determine and order the bolus and infusion rate of his/her choice. 7e
7 INTEGRILIN (EPTIFIBATIDE) DOSING CHART FOR PATIENTS WITH ACUTE CORONARY SYNDROME (180 mcg/kg Bolus and 2 mcg/kg/min Infusion) Patient Bolus Infusion Weight Volume Rate (kg) (2 mg/ml) (0.75 mg/ml) ml 6ml/hr > INTEGRILIN (EPTIFIBATIDE) DOSING CHART BY WEIGHT FOR PATIENTS WITHOUT ACUTE CORONARY SYNDROMES UNDERGOING PCI (135 mcg/kg Bolus and 0.5 mcg/kg/min Infusion) Patient Bolus Infusion Weight Volume Rate (kg) (2 mg/ml) (0.75 mg/ml) ml 2 ml/hr g
PRODUCT MONOGRAPH. Pr INTEGRILIN. Eptifibatide Injection Intravenous Solution. 2 mg/ml bolus Injection 0.75 mg/ml Injection (as infused)
PRODUCT MONOGRAPH Pr INTEGRILIN Injection Intravenous Solution 2 mg/ml bolus Injection 0.75 mg/ml Injection (as infused) Platelet Aggregation Inhibitor Merck Canada Inc. Date of Preparation: 16750 route
More informationBOLUS VIAL + INFUSION
INDICATIONS AND USAGE AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/ repeat cardiac procedure)
More informationDOSING AND ADMINISTRATION
DOSING AND ADMINISTRATION USING 100 ML VIAL OR 250 ML BAG (50 MCG/ML UNITS) 1 2 BOLUS 25 mcg/kg within 5 minutes INFUSION CrCl >60 ml/min: 0.15 mcg/kg/min CrCl
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACTIVASE (t-pa) INFUSION PROTOCOL FOR ACUTE MYOCARDIAL INFARCTION
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS ACTIVASE (t-pa) FOR ACUTE MYOCARDIAL INFARCTION I. PURPOSE: A. To reduce the extent of myocardial infarction by lysing the clot in
More informationPRE-MIXED BAGS DOSING AND ADMINISTRATION. Rate (ml/hr)
Weight (lb) Weight (kg) PRE-MIXED BAGS DOSING AND ADMINISTRATION 1 2 BOLUS Using Pre-Mixed Bags 25 mcg/kg within 5 minutes Volume (ml) Rate (ml/hr) INFUSION Using Pre-Mixed Bags CrCl >60 ml/min: 0.15 mcg/kg/min
More informationAGGRASTAT (tirofiban hydrochloride) injection, for intravenous use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AGGRASTAT (tirofiban hydrochloride) safely and effectively. See full prescribing information for
More informationCONTRAINDICATIONS INDICATIONS AND USAGE WARNINGS AND PRECAUTIONS ADVERSE REACTIONS DOSAGE AND ADMINISTRATION DRUG INTERACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AGGRASTAT (tirofiban hydrochloride) safely and effectively. See full prescribing information for
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS. ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS ACUTE CEREBROVASCULAR ACCIDENT TPA (ACTIVASE /alteplase) FOR THROMBOLYSIS I. Purpose : A. To reduce morbidity and mortality associated
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationNEW ZEALAND DATA SHEET INTEGRILIN SOLUTION FOR INJECTION. INTEGRILIN Eptifibatide (20mg in 10mL and 75mg in 100mL) solution for injection.
NEW ZEALAND DATA SHEET INTEGRILIN SOLUTION FOR INJECTION NAME OF MEDICINE INTEGRILIN Eptifibatide (20mg in 10mL and 75mg in 100mL) solution for injection. PRESENTATION INTEGRILIN is a clear, colourless
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationBIVASTAT Injection (Bivalirudin)
Published on: 1 Aug 2014 BIVASTAT Injection (Bivalirudin) Compostion BIVASTAT Each vial contains: Bivalirudin.. 250 mg Excipients.q.s. Supplied with 5 ml Sterile Water for Injection, IP Dosage Form Sterile
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT INTEGRILIN 0.75 mg/ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution for infusion contains
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationGUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE
2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American
More informationObjectives. Treatment of ACS. Early Invasive Strategy. UA/NSTEMI General Concepts. UA/NSTEMI Initial Therapy/Antithrombotic
Objectives Treatment of ACS Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Define early invasive strategy and what patients typically receive this approach Compare/contrast the medications
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationST. DOMINIC-JACKSON MEMORIAL HOSPITAL JACKSON, MISSISSIPPI. CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) HEPARIN ANTICOAGULATION Page 1 of 5
HEPARIN ANTICOAGULATION Page 1 of 5 Pharmacy Mnemonic: CRRTHEP1 PATIENT DATA: DIAGNOSIS: AKI ESRD Other: WEIGHT: Today: kg Admission Weight:: kg Dry Weight: kg Access TYPE: Temporary Dialysis Catheter
More informationWhen the learner has completed this module, she/he will be able to:
Thrombolytics and Myocardial Infarction WWW.RN.ORG Reviewed September 2017, Expires September 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017
More information6 th Floor and 7 East Nurses Guide Intravenous Drip List Approved for RN Administration University of Kentucky Chandler Medical Center
RATE Abciximab (Reopro) Alteplase (tpa, Activase) All units 6S and 6W ONLY Platelet aggregation inhibitor Thrombolytic agent Bolus: 0.25 mg/kg IV over 5 min Infusion: 0.125 0.9 mg/kg (max 90 mg); 10% of
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationCLINICAL GUIDELINES ID TAG
Title: Author: Speciality/ Division: Directorate: Date Uploaded: Review Date: September 2019 CG ID TAG CG0423 CLINICAL GUIDELINES ID TAG Clinical Guideline for Alteplase in intra-arterial thrombolysis
More informationADULT POST NEUROLOGIC INTERVENTION ORDERS 2 of 4
9 Actual 9 Estimated DOWNTIME INTERVENTION 1 of 4 Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Admit to Dr.: Bed Type: Dx: ( ) Check, circle and/or fill in all
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationDiagnosis and Management of Acute Myocardial Infarction
Diagnosis and Management of Acute Myocardial Infarction Acute Myocardial Infarction (AMI) occurs as a result of prolonged myocardial ischemia Atherosclerosis leads to endothelial rupture or erosion that
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationDrug Max dose approved for IVP Dilution Rate Monitoring Parameters. Dilution not necessary (Available in prefilled syringe)
Drug Max dose approved for IVP Dilution Rate Monitoring Parameters Acetazolamide 500 mg Reconstitute with at least 5ml sterile water (max concentration should not exceed 100mg/ml) 100-500 mg/min Hypotension
More informationPhysician Orders ADULT
Physician Orders ADULT attach patient label here Order Set: ED Non-STEMI Unstable Angina Orders Height: cm Weight: kg Allergies: No known allergies Medication allergy(s): Latex allergy Other: Admission/Transfer/Discharge
More informationDATA SHEET. REOPRO vial 5 ml contains 10 mg abciximab rmc. REOPRO is a clear, colourless, sterile solution for intravenous use.
DATA SHEET REOPRO Abciximab rmc, solution for injection, vials 2 mg/ml. Presentation REOPRO vial 5 ml contains 10 mg abciximab rmc. REOPRO is a clear, colourless, sterile solution for intravenous use.
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationPRODUCT INFORMATION INTEGRILIN INJECTION
PRODUCT INFORMATION INTEGRILIN INJECTION NAME OF THE MEDICINE Eptifibatide Chemical structure: Chemical Name: CAS Registry No.: 157630-07-4 cyclo(s-s)-mercaptopropionyl-l-homoarginylglycyl-l-aspartyl-
More informationCardiac Catheter Labs Intravenous Drug Therapy Guide
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationPackage leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab
Package leaflet: Information for the user ReoPro 2 mg/ml solution for injection or infusion abciximab Read all of this leaflet carefully before you start using this medicine because it contains important
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationHow to give thrombolysis in acute myocardial infarction
Page 1 of 6 How to give thrombolysis in acute myocardial infarction Original article: Michael Tam In the major urban hospitals, there will be little place for thrombolysis in acute STEMI (STelevation myocardial
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationNitroglycerin and Heparin Drip Interfacility Protocols
Nitroglycerin and Heparin Drip Interfacility Protocols EMS Protocol This protocol applies to nitroglycerin and Heparin drips that are initiated at the transferring facility prior to transport and are not
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Aggrastat (250 micrograms/ml) concentrate for solution for infusion tirofiban
PACKAGE LEAFLET: INFORMATION FOR THE USER Aggrastat (250 micrograms/ml) concentrate for solution for infusion tirofiban Read all of this leaflet carefully before you start using this medicine because it
More informationS PECIAL A RTICLE. Combination Antiplatelet Therapy: Implications for Pharmacists
S PECIAL A RTICLE Combination Antiplatelet Therapy: Implications for Pharmacists Robert L. Talbert, Pharm.D., FCCP, Sarah A. Spinler, Pharm.D., FCCP, Jean M. Nappi, Pharm.D., FCCP, and Michael B. Bottorff,
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments
ADENOSINE Paroxysmal SVT 1 st Dose 6 mg rapid IV 2 nd & 3 rd Doses 12 mg rapid IV push Follow each dose with rapid bolus of 20 ml NS May cause transient heart block or asystole. Side effects include chest
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationDiagnosis: Allergies with reaction type:
Patient Name: Diagnosis: Allergies with reaction type: ICU Stroke-Ischemic S/P tpa Version 2 5/29/14 This order set is designed to be used with an admission set or for a patient already admitted Nursing
More informationAcute Coronary Syndrome (ACS) Initial Evaluation and Management
Acute Coronary Syndrome (ACS) Initial Evaluation and Management Symptoms of Possible ACS Chest discomfort with or without radiation to the arm(s), jaw, or epigastrium Short of breath Weakness Diaphoresis
More informationNURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOL USE OF PROPOFOL (DIPRIVAN) FOR VENTILATOR MANAGEMENT
NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOL I. PURPOSE: To provide guidelines for the administration of Propofol, which is an anesthetic agent, indicated for the continuous intravenous
More informationUTMB DEPARTMENT OF PHARMACY POLICY AND PROCEDURES Section Medication Use ADMINISTRATION OF MEDICATION BY IV PUSH
Page 1 of 8 ADMINISTRATION OF MEDICATION BY IV PUSH AUDIENCE POLICY This document is directed to Registered Nurses (RNs), Licensed Vocational Nurses (LVN s), and physicians. The following delineates the
More information2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Bypass Graft (CABG) (for patients aged 18 years and older)
2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Bypass Graft (CABG) (for patients aged 18 years and older) IMPORTANT: Any measure with a 0% performance rate (100% for inverse
More informationNOTICES DEPARTMENT OF HEALTH
NOTICES DEPARTMENT OF HEALTH Approved Drugs for ALS Ambulance Services [42 Pa.B. 4229] [Saturday, July 7, 2012] Under 28 Pa. Code 1005.11(b) (relating to drug use, control and security), the following
More informationChest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
Patient Name: Diagnosis: Allergies with reaction type: Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationChapter 10 Worksheet Blood Pressure and Antithrombotic Agents
Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances
More informationSupplementary Table 1. Details of the components of the primary composite endpoint
Supplementary Table 1. Details of the components of the primary composite endpoint 1. Death The cause of death will be defined by the underlying cause, not the immediate mode of death. Death will be classified
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationPRODUCT INFORMATION. Concentrate for IV infusion. AGGRASTAT (tirofiban hydrochloride) DESCRIPTION
ARS-012001s 1 PRODUCT INFORMATION Concentrate for IV infusion AGGRASTAT (tirofiban hydrochloride) DESCRIPTION AGGRASTAT (tirofiban hydrochloride, MSD), a non-peptide antagonist of the platelet glycoprotein
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
Available at ALL facilities Non Categorized SUB ED Chest Pain: STEMI Protocol(SUB)* SUB ED Chest Pain: STEMI Protocol Lab Orders(SUB)* ED Rainbow Tubes(SUB)* ***Reminder: Order ED Rainbow Tubes (SUB) as
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Aggrastat (50 micrograms/ml) solution for infusion tirofiban
PACKAGE LEAFLET: INFORMATION FOR THE USER Aggrastat (50 micrograms/ml) solution for infusion tirofiban Read all of this leaflet carefully before you start using this medicine because it contains important
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationAccess Site Complications. Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary s Hospital Campus
Access Site Complications Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary s Hospital Campus Surgeons & Cardiologists Interventional Cardiology 2008 Eye of a Hawk,
More informationFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE. 1.1 Percutaneous Transluminal Coronary Angioplasty (PTCA)
451129B/Revised: June 2016 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BIVALIRUDIN FOR INJECTION safely and effectively. See full prescribing
More informationPEDIATRIC LIFEGIFT BRAIN DEATH PLAN
PHYSICIAN S Diagnosis Weight Allergies Admit/Discharge/Transfer THIS PLAN IS TO BE ED ONLY ON THE LIFEGIFT ENCOUNTER, WITH DR LIFEGIFT AS THE ATTENDING. Patient Status Pt Status: Inpatient (Inpatient only
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationSTANDARDIZED PROCEDURE CARDIAC STRESS TESTING-DOBUTAMINE INFUSION (Adult)
I. Definition: This test is performed to evaluate for cardiac ischemia, arrhythmias, and/or response to exercise. II. Background Information A. Setting: The setting (inpatient vs outpatient) and population
More informationIR Central Venous Access [ ] Pre Procedure
IR Central Venous Access [1050200001] Pre Procedure Case Request/Scheduling Procedure Enter IR Case Request if not already completed (All hospitals except Grant Medical Center) [ ] Case Request IR Lab
More informationThrombolysis administration
Thrombolysis administration Liz Mackey Stroke Nurse Practitioner Western Health Sunshine & Footscray Hospital, Melbourne Thanks ASNEN committee members Skye Coote, Acute Stroke Nurse, Eastern Health (slide
More informationTherapeutic Hypothermia for Post Cardiac Arrest Plan Initial Orders
Arrest Plan Initial Orders Weight Allergies Therapeutic Hypothermia Guidelines ***Required to continue with ordering Plan.*** Strict Intake and Output q1h, throughout cooling and re warming. Set Up for
More informationPatient characteristics Intervention Comparison Length of followup
ANTICOAGULANT CHAPTER Low Molecular Weight Heparins compared with Unfractionated Heparin Ref ID: 1903 Reference Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic
More informationCase report. Open Access. Abstract
Open Access Case report A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports Hima Mikkilineni, Steven R Bruhl, William R
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationDAY1_CARDIOVASCULAR PRACTICE QUESTIONS
DAY1_CARDIOVASCULAR PRACTICE QUESTIONS 1 P age 1. A 59-year-old male is admitted complaining of chest pain and dyspnea. ST elevation and T-wave inversion were seen on the ECG in V2, V3, and V4. IV thrombolytic
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationST Elevation Myocardial Infarction (STEMI) Reperfusion Order Set
Form Title Form Number CH-0454 2018, Alberta Health Services, CKCM This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin 250mg for injection or infusion (Angiox ) (156/05) Nycomed UK Ltd No. 4 February, 2005 The Scottish Medicines Consortium has completed its assessment of the above
More information** Medication exercises ** NICU Phase II
** Medication exercises ** NICU Phase II A) Baby A has had a bowel resection six hours ago. She weighs 3 kg. Postop, she is quite agitated and she is on a fentanyl drip at 2 micrograms/kg/hr (#1). She
More informationCardiac Catheterization, Coronary Angiogram, and Percutaneous Coronary Intervention (PCI)
Cardiac Catheterization, Coronary Angiogram, and Percutaneous Coronary Intervention (PCI) Cardiac Catheterization, Coronary Angiogram, and Percutaneous Coronary Intervention (PCI) Your doctor has recommended
More informationDOBUTamine INJECTION, USP R x only
DOBUTamine INJECTION, USP R x only DESCRIPTION Dobutamine Injection, USP is 1,2-benzenediol, 4-[2-[[3-(4-hydro-xyphenyl)-1- methylpropyl]amino]ethyl]-hydrochloride, (±). It is a synthetic catecholamine.
More informationCardiovascular Concerns in Intermediate Care
Cardiovascular Concerns in Intermediate Care GINA ST. JEAN RN, MSN, CCRN-CSC CLINICAL NURSE EDUCATOR HEART AND & CRITICAL AND INTERMEDIATE CARE Objectives: Identify how to do a thorough assessment of the
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
Available at: BMC-B BMC-D BMC-N BMC-S Activity Activity Bedrest with BRP, with assistance at nurse's discretion (DEF)* Ambulate with Assistance Diet Communication Order Patient to remain NPO while in PACU
More informationARGATROBAN Injection PRESCRIBING INFORMATION
ARGATROBAN Injection PRESCRIBING INFORMATION DESCRIPTION Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. The chemical name for Argatroban is 1-[5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationPreoperative Cardiac Risk Assessment: Approach & Guidelines
Preoperative Cardiac Risk Assessment: Approach & Guidelines By, Liam Morris, MD., FACC (02/03/18) CPG : Clinical Practice Guidelines GDMT : Guidelines Directed Medical Therapy GWC : Guideline Writing Committee
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 ANGIOX 250 mg, powder for concentrate for solution for injection or infusion by the intravenous route
More informationClinical Lessons from BMC2-PCI
Clinical Lessons from BMC2-PCI The Blue Cross Blue Shield of Michigan Cardiovascular Consortium Hitinder Gurm, M.D. University of Michigan Overview 32 papers since inception 10 papers published this year
More informationClinical Therapeutics/Volume 31, Number 8, 2009
Clinical Therapeutics/Volume 31, Number 8, 2009 Assessment of the Bioequivalence of Brand and Biogeneric Formulations of Abciximab for the Treatment of Acute Coronary Syndrome: A Prospective, Open-Label,
More informationBlanchard Valley Hospital Pharmacy Code Blue Overview
Blanchard Valley Hospital Pharmacy Code Blue Overview Adapted from Gary Spanik, RPh Edited by Kate Reeves, Pharm D, RPh Jon Manocchio, Pharm D, RPh Pharmacist Responsibilities Be aware of basic ACLS tenets
More information* * FORM REV. 02/2019 Page 1 of 4. TNKASE (tenecteplase) / ACUTE STEMI ORDERS SCHEDULED MEDICATIONS:
1. Is this a CMS inpatient only procedure? Yes, admit as inpatient, proceed to # 3 No, proceed to # 2 2. Do you expect that the patient s condition will require a hospital stay that will cross two midnights
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More information** Medication exercises ** NICU Phase II
** Medication exercises ** NICU Phase II A) Baby A has had a bowel resection six hours ago. She weighs 3 kg. Post-op, she is quite agitated and she is on a fentanyl drip at 2 micrograms/kg/hr (#1). She
More informationPOST-OP CARDIAC SURGERY PHYSICIAN S ORDER SHEET USE BALLPOINT PEN ONLY. CARDIAC INTENSIVE CARE UNIT
PHYSICIAN S SHEET Automatically Activate, if not in agreement, cross out and initial Activated by Checking Box ALLERGIES: None known YES Patient s Height: Patient s Weight: ALL MEDICATION and INTRAVENOUS
More informationCardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention
Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More information